All In Biotech

Drug Trial Radar · NCT01290939

Bevacizumab and Lomustine for Recurrent GBM

Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Last checked: Nov 20, 2026Latest source record: Feb 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 592 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

592

Actual

Start

Oct 2011

Primary completion

Oct 2015

Study completion Apr 2020

Sponsor

Sponsor type
Research network
Collaborators
Hoffmann-La Roche
First posted
Feb 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of bevacizumab given together with lomustine is most effective in treating patients with glioblastoma multiforme in first recurrence. PURPOSE: The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone.

Conditions

  • Glioblastoma Multiforme
  • Cognition Disorders
  • Disability Evaluation

Interventions

  • bevacizumabBiological

  • lomustineDrug

  • DNA methylation analysisGenetic

  • laboratory biomarker analysisOther

  • cognitive assessmentProcedure

  • quality-of-life assessmentProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Time to event

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Erasmus MC - Daniel den Hoed Cancer Center

    Rotterdam, Netherlands

  • Medisch Centrum Haaglanden - Westeinde

    The Hague, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.